Humana Inc. (NYSE:HUM) Shares Sold by Accretive Wealth Partners LLC

Accretive Wealth Partners LLC reduced its position in shares of Humana Inc. (NYSE:HUM) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,243 shares of the insurance provider’s stock after selling 83 shares during the period. Accretive Wealth Partners LLC’s holdings in Humana were worth $1,027,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Bessemer Group Inc. boosted its position in shares of Humana by 143.4% during the 1st quarter. Bessemer Group Inc. now owns 6,436 shares of the insurance provider’s stock worth $2,230,000 after acquiring an additional 3,792 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Humana by 4.5% during the first quarter. Advisors Asset Management Inc. now owns 5,370 shares of the insurance provider’s stock worth $1,862,000 after purchasing an additional 230 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Humana by 8.2% during the 1st quarter. Lazard Asset Management LLC now owns 406,993 shares of the insurance provider’s stock worth $141,110,000 after buying an additional 30,778 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Humana by 34.9% in the 1st quarter. Bellevue Group AG now owns 135,541 shares of the insurance provider’s stock valued at $46,995,000 after buying an additional 35,069 shares in the last quarter. Finally, Ceeto Capital Group LLC grew its position in shares of Humana by 30.6% in the 1st quarter. Ceeto Capital Group LLC now owns 2,560 shares of the insurance provider’s stock valued at $890,000 after buying an additional 600 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 0.8 %

NYSE:HUM opened at $296.39 on Friday. The stock has a fifty day simple moving average of $277.30 and a 200 day simple moving average of $330.79. The firm has a market capitalization of $35.69 billion, a price-to-earnings ratio of 26.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.52. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Sell-side analysts forecast that Humana Inc. will post 15.86 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s payout ratio is 31.36%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research analyst reports. KeyCorp initiated coverage on shares of Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Stephens restated an “equal weight” rating and set a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and lowered their target price for the stock from $519.00 to $253.00 in a research report on Monday, October 7th. Finally, Oppenheimer decreased their price target on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $315.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.